


Discover the Next Level of IL-17A Analysis with Quanterix® Advantage PLUS

Unlock unprecedented sensitivity and precision in IL-17A analysis with Quanterix® IL-17A Advantage PLUS, the latest innovation in our Simoa® bead assay platform.

Whether you are researcher pushing the boundaries of discovery or evaluating anti-IL-17A therapeutic agents, the IL-17A Advantage PLUS kit (104428) redefines the standards of quantitation, enabling you to delve deeper into the intricacies of human plasma and serum samples with unparalleled accuracy.



IL-17A Advantage PLUS



What Sets Simoa® IL-17A Advantage PLUS Apart?

- **Unmatched Sensitivity and Precision:** Achieve reliable quantitation of IL-17A down to the femtogram level.
- **Versatile Compatibility:** Compatible with challenging clinical samples like serum and EDTA-plasma.
- **Optimized for Longitudinal Studies:** Support for large-scale or longitudinal studies with large lot size and excellent lot-to-lot consistency.
- **Efficiency Through Automation:** Streamlined and scalable workflow with full automation enabled on the HD-X platform.
- **Proven Technology:** Part of a large and growing Simoa® digital immunoassay menu cited in over 2600 publications.
- **Reduced Carbon Footprint:** Efficient packaging and shipping minimize energy consumption and emissions, promoting environmental sustainability.

Unlock the Potential of Your Research

Experience the future of IL-17A analysis with Simoa® IL-17A Advantage PLUS. Elevate your research capabilities, uncover new insights, and accelerate scientific breakthroughs. Visit the www.quanterix.com for more information and to explore our full range of Simoa® Assay Kits.



Assay Performance at a Glance

Simoa® IL-17A Advantage PLUS	
Analytical LLOQ	0.006 pg/mL Pooled CV 18% Mean Recovery 107%
Functional LLOQ (serum & EDTA plasma)	0.012 pg/mL
LOD	0.002 pg/mL SD 0.001 pg/mL
Dynamic Range (serum & EDTA plasma)	0 - 24 pg/mL
Detectability	EDTA Plasma: 100% Serum 98%
Quantifiability	EDTA Plasma: 82% Serum: 83%

IL-17A in Action

A sampling of recent peer-reviewed publications using Simoa® IL-17A assays include:

Evaluation of plasma IL-21 as a potential biomarker for type 1 diabetes progression

Front Immunol. 2023

doi:10.3389/fimmu.2023.1157265

Characterization of Blood Mucosal-Associated Invariant T Cells in Patients With Axial Spondyloarthritis and of Resident Mucosal-Associated Invariant T Cells From the Axial Entheses of Non-Axial Spondyloarthritis Control Patients

Arthritis Rheumatol. 2022

doi:10.1002/art.42090

Phenotypic Heterogeneity of Fulminant COVID-19--Related Myocarditis in Adults

J Am Coll Cardiol. 2022

doi:10.1016/j.jacc.2022.04.056

High Level of Inflammatory Cytokines in the Tears: A Bridge of Patients with Concomitant Exotropia and Dry Eye

Oxid Med Cell Longev. 2021

doi:10.1155/2021/5662550